Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
European Society for Paediatric Endocrinology, 2024 (ESPE)
Pharmacodynamic endpoints after once-weekly Somapacitan in children with GHD: 3-year results from REAL4 phase 3 study
European Society for Paediatric Endocrinology, 2024 (ESPE)
:
{{ getPageNum(PDFPage) }}